Synlogic (LTS:0A8U) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Synlogic LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Synlogic's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Synlogic's long-term debt to total assets ratio declined from Sep. 2023 (0.21) to Sep. 2024 (0.00). It may suggest that Synlogic is progressively becoming less dependent on debt to grow their business.

Synlogic LT-Debt-to-Total-Asset Historical Data

The historical data trend for Synlogic's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic LT-Debt-to-Total-Asset Chart

Synlogic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.14

0.10

0.15

0.17

Synlogic Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.21	0.17	0.33	-	-

Synlogic LT-Debt-to-Total-Asset Calculation

Synlogic's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	12.491	/	75.55
	=	0.17

Synlogic's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0	/	20.755
	=

Synlogic (LTS:0A8U) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Synlogic LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Synlogic's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Synlogic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (LTS:0A8U) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SYBX:USA

Address

301 Binney Street, Suite 402, Cambridge, MA, USA, 02142

Website

https://www.synlogictx.com

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Synlogic Headlines

No Headlines